{"created":"2023-05-15T09:48:36.193418+00:00","id":11465,"links":{},"metadata":{"_buckets":{"deposit":"e3e24128-7a3a-4f57-903e-0d719667cb42"},"_deposit":{"created_by":11,"id":"11465","owners":[11],"pid":{"revision_id":0,"type":"depid","value":"11465"},"status":"published"},"_oai":{"id":"oai:kagawa-u.repo.nii.ac.jp:00011465","sets":["13:40"]},"author_link":["3972"],"item_10006_date_granted_11":{"attribute_name":"学位授与年月日","attribute_value_mlt":[{"subitem_dategranted":"2022-09-30"}]},"item_10006_degree_grantor_9":{"attribute_name":"学位授与機関","attribute_value_mlt":[{"subitem_degreegrantor":[{"subitem_degreegrantor_language":"ja","subitem_degreegrantor_name":"香川大学"},{"subitem_degreegrantor_language":"en","subitem_degreegrantor_name":"Kagawa University"}],"subitem_degreegrantor_identifier":[{"subitem_degreegrantor_identifier_name":"16201","subitem_degreegrantor_identifier_scheme":"kakenhi"}]}]},"item_10006_degree_name_8":{"attribute_name":"学位名","attribute_value_mlt":[{"subitem_degreename":"博士（医学）","subitem_degreename_language":"ja"}]},"item_10006_description_7":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Objectives: Indications of preoperative treatment for resectable (R-) or borderline resectable (BR-) pancreatic ductal adenocarcinoma (PDAC) are unclear, and the protocol remains to be standardized.","subitem_description_language":"en","subitem_description_type":"Abstract"},{"subitem_description":"Methods: Included 65 patients with R- and BR-PDAC with venous involvement (V-) received neoadjuvant chemoradiotherapy with S-1 and 50 Gy of radiation as the 5-week regimen. The outcomes of this group were compared with those of 52 patients who underwent S-1 and 30 Gy of radiation as the 2-week regimen, previously collected as our prospective phase II study.","subitem_description_language":"en","subitem_description_type":"Abstract"},{"subitem_description":"Results: Compared with the 2-week regimen, there were no significant differences in the rate of protocol completion, adverse events, mortality and morbidity, or R0 resection in the 5-week regimen. In subgroup analyses of R-PDAC, there were no significant differences in overall survival and recurrence-free survival between the groups. In contrast, the 5-week regimen had significantly better overall survival and recurrence-free survival than the 2-week regimen for BRV-PDAC. Similar results were observed after propensity score matching analysis.","subitem_description_language":"en","subitem_description_type":"Abstract"},{"subitem_description":"Conclusions: The 5-week regimen of neoadjuvant chemoradiotherapy has good clinical efficacy and safety for R- and BRV-PDAC. The 5-week regimen could achieve better outcomes than the 2-week regimen for BRV-PDAC. In contrast, both regimens achieved similar outcomes for R-PDAC.","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_10006_dissertation_number_12":{"attribute_name":"学位授与番号","attribute_value_mlt":[{"subitem_dissertationnumber":"甲第815号"}]},"item_10006_relation_15":{"attribute_name":"関連サイト","attribute_value_mlt":[{"subitem_relation_type":"isVersionOf","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.1097/mpa.0000000000002011","subitem_relation_type_select":"DOI"}}]},"item_10006_relation_22":{"attribute_name":"PubMed番号","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"35584385","subitem_relation_type_select":"PMID"}}]},"item_10006_rights_13":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.","subitem_rights_language":"en"},{"subitem_rights":"Embergo expiration date: 2023-03-01","subitem_rights_language":"en"}]},"item_10006_version_type_18":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_fa2ee174bc00049f","subitem_version_type":"P"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"open access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_abf2"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"須藤, 広誠","creatorNameLang":"ja"},{"creatorName":"ストウ, ヒロノブ","creatorNameLang":"ja-Kana"},{"creatorName":"Suto, Hironobu","creatorNameLang":"en"}],"nameIdentifiers":[{},{},{},{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2023-03-01"}],"displaytype":"detail","filename":"Med_A815.pdf","filesize":[{"value":"630.4 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"本文","objectType":"fulltext","url":"https://kagawa-u.repo.nii.ac.jp/record/11465/files/Med_A815.pdf"},"version_id":"8280875d-0f55-4703-aa84-effdf016ff30"},{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2022-10-18"}],"displaytype":"detail","filename":"Med_A815_abstract.pdf","filesize":[{"value":"71.4 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"内容の要旨","objectType":"abstract","url":"https://kagawa-u.repo.nii.ac.jp/record/11465/files/Med_A815_abstract.pdf"},"version_id":"8a000fef-0681-4620-8246-177885182b84"},{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2022-10-18"}],"displaytype":"detail","filename":"Med_A815_result.pdf","filesize":[{"value":"101.5 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"審査の結果の要旨","objectType":"other","url":"https://kagawa-u.repo.nii.ac.jp/record/11465/files/Med_A815_result.pdf"},"version_id":"b9634200-6655-4c52-abaa-868d29b2fa39"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"neoadjuvant therapy","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"pancreatic cancer","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"chemotherapy","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"chemoradiation","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"pancreatectomy","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"doctoral thesis","resourceuri":"http://purl.org/coar/resource_type/c_db06"}]},"item_title":"Efficacy and safety of neoadjuvant chemoradiation therapy administered for 5 versus 2 weeks for resectable and borderline resectable pancreatic cancer","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Efficacy and safety of neoadjuvant chemoradiation therapy administered for 5 versus 2 weeks for resectable and borderline resectable pancreatic cancer","subitem_title_language":"en"}]},"item_type_id":"10006","owner":"11","path":["40"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2022-10-18"},"publish_date":"2022-10-18","publish_status":"0","recid":"11465","relation_version_is_last":true,"title":["Efficacy and safety of neoadjuvant chemoradiation therapy administered for 5 versus 2 weeks for resectable and borderline resectable pancreatic cancer"],"weko_creator_id":"11","weko_shared_id":-1},"updated":"2023-10-16T02:32:28.308276+00:00"}